Pharmaceuticals, Biotechnology and Life Sciences
Assay Builds on Alzheon’s Research to Detect and Quantify Soluble Oligomers, and Enhances Phase 2 and Phase 3 Alzheimer’s Studies with Oral ALZ-801 Quantitative Assay to Monitor Alzheimer’s Disease Onset...
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced the initiation of a rolling submission of...
A Phase 2/3 trial to evaluate a new fully-human polyclonal antibody therapeutic targeted to SARS-CoV-2, called SAB-185, has begun enrolling non-hospitalized people with mild or moderate cases of COVID-19. The trial, ACTIV-2, is sponsored by the National Institute of Allergy...
Researchers from the National Institutes of Health have identified and tested a drug combination that exploits a weakness in small...
An international team of scientists has found evidence that SARS-CoV-2, the virus that causes COVID-19, infects cells in the mouth....
Pamiparib becomes the first PARP inhibitor approved in both platinum-sensitive and platinum-resistant relapsed ovarian cancer in China This marks the…
BOSTON and LOUISVILLE, Ky., May 06, 2021 (GLOBE NEWSWIRE) — Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing…
FLORHAM PARK, N.J., May 06, 2021 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused…
CHARLESTON, S.C., May 06, 2021 (GLOBE NEWSWIRE) — Today, Efferent Labs announces an expanded development collaboration with W. L. Gore…
CANTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on…
Acquisition of Zikani Therapeutics, Ribosomal Modulation Company; Combined Company Advancing Ribosomal RNA-Targeted Genetic Therapies Additional Treatment Arm Added to Ongoing…
BELTSVILLE, Md., May 06, 2021 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and…
Webcast Today at 4:30 pm Eastern TimeSOUTH SAN FRANCISCO, May 06, 2021 (GLOBE NEWSWIRE) — In a release issued under…
Enrollment ongoing in three Cellectis-sponsored Phase 1 dose-escalation clinical studies BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients…
PRINCETON, N.J., May 06, 2021 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its…
